1. Home
  2. FBIO vs ANIX Comparison

FBIO vs ANIX Comparison

Compare FBIO & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fortress Biotech Inc.

FBIO

Fortress Biotech Inc.

HOLD

Current Price

$2.67

Market Cap

91.0M

Sector

Health Care

ML Signal

HOLD

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$2.46

Market Cap

88.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FBIO
ANIX
Founded
2006
1982
Country
United States
United States
Employees
78
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
91.0M
88.8M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
FBIO
ANIX
Price
$2.67
$2.46
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$17.00
$8.67
AVG Volume (30 Days)
414.5K
100.0K
Earning Date
05-15-2026
05-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
12.82
EPS
N/A
N/A
Revenue
N/A
$210,000.00
Revenue This Year
$55.22
N/A
Revenue Next Year
$40.55
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.75
$2.44
52 Week High
$4.53
$5.46

Technical Indicators

Market Signals
Indicator
FBIO
ANIX
Relative Strength Index (RSI) 53.50 33.67
Support Level $2.47 $2.44
Resistance Level $2.84 $3.13
Average True Range (ATR) 0.16 0.14
MACD 0.01 -0.03
Stochastic Oscillator 56.43 2.56

Price Performance

Historical Comparison
FBIO
ANIX

About FBIO Fortress Biotech Inc.

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

Share on Social Networks: